Owlstone Medical
Developer of breath-based volatile organic compound (VOC) research products and services for non-invasive biomarker discovery, analytical method development, and translational studies. Activities include controlled breath sampling, sorbent-based sample handling, high-resolution GC-MS analysis, curation of a chemically validated VOC reference atlas, clinical and preclinical breath studies, and collaborative method development with regulatory agencies.
Industries
Nr. of Employees
medium (51-250)
Owlstone Medical
Patents
Products
Controlled breath-sampling systems and consumables
Sampling hardware and single-use consumables designed for gated tidal-breath collection onto sorbent cartridges for downstream TD-GC-MS analysis.
Controlled breath-sampling systems and consumables
Sampling hardware and single-use consumables designed for gated tidal-breath collection onto sorbent cartridges for downstream TD-GC-MS analysis.
Services
Analytical services for untargeted and targeted VOC profiling from breath and in vitro samples, including sample handling, TD-GC-MS analysis, data processing and reporting.
Account-based access to a chemically validated VOC reference database to support compound identification and cross-study comparisons in breath research.
Analytical services for untargeted and targeted VOC profiling from breath and in vitro samples, including sample handling, TD-GC-MS analysis, data processing and reporting.
Account-based access to a chemically validated VOC reference database to support compound identification and cross-study comparisons in breath research.
Expertise Areas
- Breath-based biomarker discovery
- VOC analytical chemistry and method development
- Clinical biomarker validation and correlation with biochemical endpoints
- Preclinical breath sampling in animal models
Key Technologies
- Thermal desorption–gas chromatography–mass spectrometry (TD-GC-MS)
- High-resolution accurate-mass GC-MS
- Multi-bed sorbent tube sampling
- CO2/pressure-triggered breath collection
News & Updates
Received funding to develop a low-cost synthetic-sensor multi-cancer early detection test for stage I detection of 30+ solid tumours and at-home screening.
Received investment to develop a breath-based test for detection and monitoring of Pseudomonas aeruginosa in cystic fibrosis using VOC analysis.
Entered collaboration to develop analytical methods to improve identification of specific chemicals in complex gaseous mixtures to support the VOC reference atlas.
Announced a $27 million USD investment to accelerate development programs in lung cancer, liver disease, and digestive disease diagnostics.
Pre-proof article reporting identification of a breath VOC (putatively 3-pentanone) correlated with biochemical and clinical outcomes in propionic acidemia, demonstrating application of breath sampling and TD-GC-MS in inborn errors of metabolism.
Received funding to develop a low-cost synthetic-sensor multi-cancer early detection test for stage I detection of 30+ solid tumours and at-home screening.
Received investment to develop a breath-based test for detection and monitoring of Pseudomonas aeruginosa in cystic fibrosis using VOC analysis.
Entered collaboration to develop analytical methods to improve identification of specific chemicals in complex gaseous mixtures to support the VOC reference atlas.
Announced a $27 million USD investment to accelerate development programs in lung cancer, liver disease, and digestive disease diagnostics.
Pre-proof article reporting identification of a breath VOC (putatively 3-pentanone) correlated with biochemical and clinical outcomes in propionic acidemia, demonstrating application of breath sampling and TD-GC-MS in inborn errors of metabolism.